Kornimate/medical-research-clean huggingface dataset:
effects of integrated treatment by traditional chinese and western medicine in reducing cardiovascular events

Conditions: Angina Pectoris; Coronary Artery Disease; Coronary Disease; Heart Disease; Cardiovascular Disease; Chest Pain; Pain; Signs and Symptoms; Arteriosclerosis

Summary: compared with standardized western medical drug therapy, this study is mainly about whether the combination of standardized western medical drug therapy and chinese medical continued treatment, can further decrease the rate of cardiovascular events for stable angina patients and change the condition of angina.

we will pick 1100 patients who are according with the ii、iii stage in chd western medical diagnosis standard, treat them with combination of standardized western medical drug therapy and chinese medical continued treatment, or only with standardized western medical drug therapy,the treat course will last 6 months. the patients will be separated in two groups: integrative treatment of chinese medicine and western medicine group(integrative group) and western medical group according to the exposure factors(whether the patients accept differentiation of tcm ) during the follow-up period, observe the main indexes: primary endpoint: all because of death, stroke, nonfatal myocardial infarction, revascularization. secondary endpoint: the events needed hospitalization which are because of (acute coronary syndrome)acs,heart failure, severe arrhythmia, and complications. secondary indexes: angina symptoms. including the attack times, lasting time, inducing factors of angina attacks, pain degree of angina, discontinue rate of nitroglycerin, and electrocardiogram.

Eligibility criteria:
inclusion criteria: 1. the patients who are according with the ii、iii stage in chd western medical diagnosis standard； 2. age between 18 and 75(including 18 and 75)； 3. signed the informed consent voluntarily. exclusion criteria: 1. the patients whose systolic pressure≥180mmhg and/or diastolic pressure≥110mmhg, have sever insufficiency of heart and lung（cardiac function﹥ⅱdegree）, sever arrhythmia（rapid atrial fibrillation, atrial flutter,paroxysmal ventricular tachycardia and so on）； 2. the patients who have myocardial infarction or vascular remodeling in last 3 months； 3. hepatic and kidney function obstacle（alt、ast\>1.5 times of normal upper limit value）； 4. the patients who cannot control blood glucose properly（fasting blood glucose\>7.0mmol/l and/ or random blood glucose\>11.0mmol/l）； 5. the patients who have stroke in late 6 months（lacunar cerebral infarction is not included）； 6. any other sever diseases such as malignant tumor； 7. the patients who attending other clinical study in late 3 months； 8. pregnant or lactating women； 9. the patients who have allergic constitution or are allergic to many drugs.

Keywords: traditional chinese medicine complementary therapies traditional chinese medicine syndrome scale
virtual reality and pain

Conditions: Pain, Postoperative; Pain; Anxiety Postoperative

Summary: determine the impact of vr-biofeedback, vr-distraction, and 360 video on pain and medication utilization in patients undergoing surgery; determine the role of anxiety and pain catastrophizing on changes in pain following vr-bf in patients undergoing surgery.


Eligibility criteria:
inclusion criteria: * ages 8 - 18 years * able to read, understand and speak english * patients in the immediate postoperative period with significant pain being followed by the acute pain service exclusion criteria: * outside the age range (\ 18 years) * history of developmental delays, uncontrolled psychiatric conditions, or neurological conditions (especially epilepsy and/or significant motion sickness/nausea/vomiting) * history of vertigo, dizziness, and/or seizure disorder * conditions that would preclude the application of the vr headset, such as surgeries of the head and neck
qol following management for pediatric ui

Conditions: Quality of Life; Incontinence

Summary: a comparison of changes between symptoms of incontinence and pediatric quality of life will be used to draw conclusions about whether differences in quality of life are noted with changes in symptoms of incontinence.

although positive physiological results are associated with successful treatment for bowel and bladder dysfunction and daytime incontinence (bd-ui), there are few studies examining the effects of treatment on quality of life (qol) for children. the purpose of our study is to determine whether successful physical therapy treatment improves qol for children with bd-ui. consent will be obtained from parents and assent from children. children will be asked to complete a global, age appropriate quality of life assessment and a quality of life instrument specific to incontinence. information will be provided by the parent through completion of a parent report instrument matched to the child's global quality of life tool as well as completion of an instrument depicting child symptoms. clinicians will report general information about related physiological changes and progress with established outcomes individualized to the child. a repeated measures manova will be used to analyze the results.

Eligibility criteria:
inclusion criteria: * children between ages 5-18 who were currently receiving conservative treatment for daytime ui with or without constipation or encopresis met inclusion criteria. exclusion criteria: * exclusion criteria included children who only had nocturnal enuresis or children with neurogenic bladders.

Keywords: quality of life pediatric incontinence
telerehabilitation in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: duchenne muscular dystrophy (dmd) is a progressive inherited disease that affects the muscles and causes functional limitations to varying degrees. it is vital to start physiotherapy follow-ups immediately after diagnosis. patients with dmd are among the most vulnerable groups who have problems in accessing physiotherapy services during the covid-19 pandemic. the aim of the study was to investigate the effects of the telerehabilitation program developed to protect the physical health of patients with dmd and not to interrupt their follow-up.

forty two patients with dmd were included in the study. 30 of them were ambulant in group 1, and 12 were non-ambulant in group 2. physiotherapy assessments were performed blindly before the program started. according to the functional levels of the individuals, 2 groups were formed. 9 physiotherapists applied the tele-rehabilitation program for 24 session (3 days in a week).

Eligibility criteria:
inclusion criteria: * able to communicate verbally and visually * older than 5 years old exclusion criteria: * the children who had undergone any surgical operations in the past 6 months, * having a severe cognitive and breathing impairment * using mechanical ventilator continually or intermittent * having a febrile infection

Keywords: duchenne muscular dystrophy telerehabilitation satisfaction
predicting breast flap necrosis by spatial frequency domain imaging

Conditions: Disorders of Skin Grafts and Flaps

Summary: the current surgical procedure for breast diseases places an emphasis on the conservation of breast skin in order to provide more optimal reconstruction. the purpose of this study is to use portable, non-contact optical imaging device developed at the beckman laser institute called spatial frequency domain imaging to detect the changes in a skin during reconstructive surgery procedure and healing process.

the researchers can use spatial frequency domain imaging instrument to measure the concentration of blood flow in the skin tissue and can determine of the changes that observed in the properties of the mastectomy flap that may be delay in healing process. the imaging device can determine the change from baseline measurement to the development of skin necrosis, wound infection, or implant extrusion.

Eligibility criteria:
inclusion criteria: * adult male and female 18 years and older scheduled for breast reconstructive surgery. exclusion criteria: * minor and pregnant women
creation of a clinical database of lumbar spine mri

Conditions: Low Back Pain

Summary: the creation of a clinical database including patients who suffer from low back pain and underwent a lumbar spine mri exam. this database will allow us to : * collect patients symptoms, medical history, and mri exams * launch the annotation of the mri exams by expert radiologists * link and relate information between the exams and the diagnostic done by the experts * train and develop a diagnostic platform for th spinal pathologies based on artificial intelligence.

low back pain is classically characterized by pain in the lower back, which may be accompanied by varying degrees of restricted mobility and pain radiating down to the feet. the management of low back pain is a global public health issue, since it represents one of the major causes of disability worldwide. degenerative disc disease (ddd) is the most common underlying pathology. these include herniated discs, pinched discs and degenerative spondylolisthesis (slippage of one vertebra in relation to its neighbor). worldwide, 266 million patients suffer from ddd every year. the socio-economic impact of these pathologies is considerable. ddd results from a variety of pathologies that may interact with each other. the diversity of these pathologies and the complexity of their interactions often lead to failure of a clear diagnosis, and consequently to inappropriate treatment. in clinical practice, mri is the reference test for the diagnosis of these pathologies, but inter-observer reliability remains moderate between 2 practitioners (sensitivity 56% and cohen's κ ⊂ \[0.41-0.6\]) or even low (κ ⊂ \[0.21-0.4\]) between 2 practitioners of different specialties. so there is still a major gap to be bridged in order to make radiologists' diagnoses more reliable and standardized. in this context, the creation of a clinical database including patient symtoms and exams is of hogh interest.thsi database will allow us to : 1. annotate the mri exams by experts radiologists in order to train and develop ai algorithms 2. create a tool to support radiologists in their diagnoses would therefore be a considerable step forward. such a tool, combined with non-invasive data, would make it possible to establish a specific diagnosis early on, the database will also allow us to develop or participate in multicentric clinical studies, at the national or international level, as well as to facilitate the identification of correlations between mri findings, the patients symptoms and the origin of the low back pain.

Eligibility criteria:
inclusion criteria: * adult patient aged ≥ 18, no age limit; * suffering of low back pain ; * patient exam performed at the centre hospiralier universitaire de montreal (chum), canada exclusion criteria: * patients with orthopedic material * patients with traumatic cases (ex : accidents)

Keywords: low back pain mri
investigating variation in hospital acute coronary syndrome outcomes

Conditions: Acute Myocardial Infarction

Summary: to investigate the causes of hospital variation in outcomes from acute coronary syndromes in england and develop recommendations for improving patient care.

over the last few years the chance of dying from a heart attack in england and wales has reduced dramatically. even so, there remain huge differences in mortality between hospitals. for example, up to a third of patients with a heart attack who attend hospitals in england are more likely to die than would be expected. that is, the type of treatment and the risk of death depends upon where a patient lives and which hospital they attend. in part, the variation in death may be due to the services available at the hospital or to factors such as socioeconomic deprivation. it may also relate to other factors such as depression, cardiac rehabilitation and whether patients take their medication after discharge from hospital. using powerful statistical approaches that include measures of quality of life, we propose to examine data about heart attacks in england and investigate the 'postcode lottery of care'. our aim, using regional data about heart attacks is to identify and measure the effects of hospital care. this research will identify hospital qualities that promote improved patient care. in doing so, best practice will be highlighted and healthcare policy changed so that all patients will have an equal chance of surviving a heart attack.

Eligibility criteria:
inclusion criteria: * age \> 18 years * both sexes * acute admission to the acute trust with suspected acute coronary syndrome exclusion criteria: * patients at a terminal stage of any illness * those in whom follow up would be inappropriate or impractical

Keywords: quality of life drug adherence drug compliance mortality
lc-plasma for preventing urtis and reducing symptoms

Conditions: Healthy Volunteer; URTI

Summary: the goal of this study is to evaluate the efficacy of the lc-plasma in preventing upper respiratory tract infections (urtis) in healthy volunteers. researchers will compare lc-plasma to placebo to see if lc-plasma prevents urtis. participants will take a tablet containing lc-plasma or placebo daily for 24 weeks.


Eligibility criteria:
inclusion criteria: * adults aged 18-60 years living in australia * individuals with a history of recurrent upper respiratory tract infections * able to provide informed consent * generally healthy * agree to not participate in another clinical trial while enrolled in this trial * agree to maintain their usual daily activities without significant changes. this includes not changing their current diet or stopping/starting a new exercise regimen during entire study period * agree not to travel internationally for over 1 month in a single trip during the intervention period (baseline to study completion). * females of childbearing potential must a prescribed form of birth control exclusion criteria: * serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, neurological disorders such as multiple sclerosis. * unstable illness e.g., changing medication/treatment. * bmi \ 30 * current malignancy (excluding basal cell carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years. * individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease). * has current symptoms of an acute sickness. * active smokers, nicotine use or drug (prescription or illegal substances) abuse * current alcohol use (\>14 alcoholic drinks week) * allergic to any of the ingredients in the active or placebo formula * pregnant or lactating woman * people medically prescribed medications within the last month that would affect the immune and/or the inflammatory response excluding topical steroid use. * participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month * participants with cognitive damage * participants with seasonal allergic rhinitis * regular use of antihistamines * individuals deemed unsuitable for participation by the principal investigator (pi) of this study.

Keywords: lc-plasma urti healthy volunteer
to demonstrate the relative bioavailability of cetirizine hydrochloride/pseudoephedrine hydrochloride 5 mg/120 mg extended release (er) tablets under fasting conditions

Conditions: Allergies

Summary: to demonstrate the relative bioavailability of cetirizine hydrochloride/pseudoephedrine hydrochloride 5 mg/120 mg er tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
change in patient-reported outcomes in copd patients newly initiated on trixeo aerosphere in real world

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to describe patients' clinical and self-reported outcomes of treatment with budesonide / glycopyrronium / formoterol metered dose inhaler (bgf mdi) in romania in real-life setting, up to 6 month of observation period. the study will focus primarily on the change in self-perceived health status in the first 12 weeks (3 months) of treatment with no pre-defined hypothesis.

this is a prospective, non-interventional, multi-centre study to investigate the change in patient-reported outcomes in moderate to severe copd patients newly initiated on trixeo aerosphere (budesonide / glycopyrronium / formoterol) in real-life setting in romania. furthermore, the patient satisfaction with the medication taken shall be assessed in the real-world setting; an important component that is not usually captured by rcts. patients with moderate to severe copd who are eligible for bgf mdi therapy may be enrolled by physicians in the specialist care setting and the decision to prescribe bgf mdi must be independent of enrollment into the study. this is a combined primary and secondary data collection study conducted to characterize the population of patients with copd initiating triple therapy with bgf mdi in real-life setting. thus, exposure data collected in this study will be primarily on bgf mdi treatment indicated for moderate to severe copd patients as part of routine medical care. primary data collection includes pros; all other data will be documented based on the existing medical records (secondary data collection), either historically or throughout the period of 6-month follow-up, as part of the routine practical care of the patients.

Eligibility criteria:
inclusion criteria: * physician-diagnosed copd * initiated treatment with bgf mdi as prescribed according to the summary of product characteristics (smpc) and local market reimbursement criteria; * patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol * after full explanation, patients must have signed an informed consent document indicating that they understand the purpose of, and the procedures required for the study and are willing to participate in the study exclusion criteria: * copd due to known α-1 antitrypsin deficiency * previous treatment with triple fixed-dose combination in 12 months prior to baseline * hospitalization due to copd exacerbation within the last 30 days prior to index date * pregnancy or lactation period * other uncontrolled disease, that might, in the investigator's opinion, influence the assessment for the current study * participation in a non-interventional, observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in any interventional clinical trial in the last 30 days prior to baseline. * hospitalization for covid-19 infection in the last 30 days prior to index date
treatment of acute lymphoblastic leukemia ph '(bcr / abl) positive patients aged > 55 years

Conditions: Acute Lymphoblastic Leukemia Ph Positive

Summary: this study proposes to provide adequate treatment and is based on current scientific evidence for elderly patients with all bcr / abl positive. to determine whether low-dose chemotherapy associated with imatinib or dasatinib has acceptable tolerability in elderly patients. to determine whether this association can increase the rate and quality of referrals to the results of the literature of imatinib as monotherapy for elderly patients

prephase (days -5 to -1) dexamethasone 10 mg/m2 bolus day ev for 5 days (-5 to -1). intrathecal treatment (diagnosis and prophylactic / therapeutic) -5 days: methotrexate 12 mg systemic treatment: * imatinib 400 mg daily and continuous vo. * vincristine (vcr) 1 mg (absolute dose) ev 1, 8, 15 and 22. * dexamethasone (dex): 10 mg/m2 ev, im or po days 1-2, 8-9 days 15-16, 22-23. . intrathecal chemotherapy: triple therapy was administered with methotrexate (mtx), cytosine arabinoside (ara-c) and hydrocortisone, days 1, 8, 15 and 22 (five doses total prophylactic between prophase and induction): mtx 12 mg ara-c 40 mg dexamethasone 4 mg maintenance during the first year will start after full recovery after induction and after complete reassessment of the disease (including mielograma and bcr-abl/abl or bcr-abl/gus ratio in peripheral blood) and will last until one year from the time of complete remission. the basic treatment included imatinib 400 mg / day (or dasatinib), mercaptopurine at doses of 50 mg/m2 po day and methotrexate 20 mg/m2 im weekly. one week every 3 months maintenance treatment added a "mini-reinduction" consisting * vcr: 1 mg (absolute dose), i.v., day 1. * dexamethasone 40 mg / day, i.v. or p.o., days 1-2. * not considered more doses of triple intrathecal therapy. reinduction only be practiced during the first year after remission, so a total of 4 quarterly. maintenance treatment of second year after the first year of maintenance will perform a complete reassessment of the disease (including myelogram) and if the patient remains in complete remission maintenance will continue (without reinduction) until two years from the time of diagnosis. maintenance treatment of third year during the third year after complete remission imatinib administered alone (or dasatinib

Eligibility criteria:
inclusion criteria: adults over 55 years diagnosed with acute lymphoblastic leukemia ph 'positive (bcr / abl positive) and previously untreated exclusion criteria: 1. other lal negative for t (9; 22) and bcr / abl. 2. biphenotypic acute leukemias or bilinear with t (9; 22). 3. blast crisis of chronic myeloid leukemia progression during or after polychemotherapy treatment (including allo-bmt) or with inhibitors of tyrosine kinases. the criteria for exclusion from treatment (but not patient record) any of the following 4. general condition affected (grades 3 and 4 who scale), not attributable to the lal. 5. lack of consent by the patient to use their clinical d